Why is Lexicon Pharmaceuticals stock surging today?
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lexicon Pharmaceuticals Inc (LXRX)
The Lexicon share price today is 1.820, view NASDAQ LXRX stock exchange data. Track the latest Lexicon share price with real-time updates on LXRX stock performance including market cap, day range, 52-week range and dividend yield. Access LXRX charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.800
1.870
52 wk Range
1.100
2.680
LXRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.8001.870
52 wk Range
1.1002.680
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LXRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
4.547
Upside
+149.82%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.547
(+149.82% Upside)
Lexicon Pharmaceuticals Inc Earnings Call Summary for Q2/2026
- Lexicon reported Q2 2026 loss of $0.07/share vs. $0.05 expected; revenue beat at $28.9M vs. $4.0M forecast driven by licensing income.
- Shares fell 13.27% to $2.125 in premarket trading despite revenue beat, as investors focused on wider-than-expected loss and delayed catalysts.
- Company completed enrollment in SONATA-HCM Phase III trial; expects top-line data Q1 2027 and ZYNQUISTA NDA resubmission by October 2026.
- Cash position strengthened to $190.6M from $125.2M year-end 2025 via capital raise and $100M Hercules debt facility; 2026 opex guidance $100-110M.
- Management highlighted SONATA-HCM over-enrollment for improved statistical power; emphasized sotagliflozin as novel HCM treatment across disease spectrum.
Last Updated: 06-08-2026, 06:56 pm
Read Full TranscriptEarnings
Latest Release
06-08-2026
EPS / Forecast
-0.07 / -0.05
Revenue / Forecast
28.9M / 4M
Compare LXRX to Peers and Sector
Metrics to compare | LXRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLXRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.3x | −2.2x | −0.4x | |
PEG Ratio | −0.25 | −0.02 | 0.00 | |
Price/Book | 4.6x | 3.3x | 2.6x | |
Price / LTM Sales | 19.5x | 26.6x | 3.0x | |
Upside (Analyst Target) | 149.8% | 364.1% | 58.2% | |
Fair Value Upside | Unlock | 13.9% | 7.7% | Unlock |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Lexicon (LXRX) Share Price Today?
The Lexicon share price today is 1.820.
What is the current Lexicon (LXRX) share price and day range?
As of 04-10-2026, the Lexicon share price is 1.820, with a previous close of 1.820. The share price has ranged from 1.800 to 1.870 today, while the 52-week range spans from 1.100 to 2.680.
What Is the Lexicon Market Cap?
As of today, Lexicon market cap is 809.820M.
What Is the Lexicon (LXRX) Share Price Target?
The average 12-month share price target for Lexicon is 4.547, with a high estimate of 8 and a low estimate of 2. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +149.82% Upside potential.
What Is Lexicon's Earnings Per Share (TTM)?
The Lexicon EPS (TTM) is -0.159.
When Is the Next Lexicon Earnings Date?
Lexicon will release its next earnings report on 11-11-2026.
From a Technical Analysis Perspective, Is LXRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Lexicon Trade On?
Lexicon is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Lexicon?
The stock symbol for Lexicon is "LXRX."
How Many Times Has Lexicon Stock Split?
Lexicon has split 1 times.
How Many Employees Does Lexicon Have?
Lexicon has 81 employees.
What Is the LXRX Premarket Price?
LXRX's last pre-market stock price is 1.850. The pre-market share volume is 2,520.000, and the stock has changed by 0.030, or 1.650%.
What Is the LXRX After Hours Price?
LXRX's last after hours stock price is 1.808, the stock has changed by -0.012, or -0.680%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.